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Thirty-two consecutive children aged 0–18 years with VTE treated with LMWH administered as a continuous infusion (CI) were
identiﬁed at the Children’s University Hospital Brno. The treatment led to at least partial resolution of the thrombus within
two weeks in 85% of patients. There were no adverse events or increased bleeding reported in any patients. No recurrences
were observed during a followup period of 6 months. Although continuous infusion should not replace subcutaneous (SC)
administration of LMWH, CI appeared to be safe and eﬃcient and may provide an alternate method of administering LMWH
in a subset of the paediatric population where SC administration may not be feasible. Further prospective studies are needed to
support the promising ﬁndings of our pilot clinical observation.
1.Introduction
The incidence of VTE-venous thromboembolism (deep vein
thrombosis, pulmonary embolism) is age dependent with
the lowest risk occurring in children [1–3]. The estimated
incidence of deep vein thrombosis (DVT) and pulmonary
embolism (PE) in the general paediatric population is
0.07/10 000 and 5.3/10 000 among hospital admissions,
respectively [4–7]. In the last decade, however, the incidence
of VTE in children appears to be increasing probably
because ofincreased awareness of theproblemand improved
diagnostic methods [8, 9]. DVT/PE develops in children
often as a secondary complication of other underlying
disorders. These prothrombotic risk factors can be either
inherited or acquired. Inherited prothrombotic risk factors
are responsible for only 5–7% of VTE in children [6, 7].
Idiopathic VTE occurs in less than 1% of newborns, and in
less than 5% of children compared to approximately 40%
of adults [6, 7, 10, 11]. Children less than one year of age
and teenagers appear to be at a higher risk for developing
secondary VTE [6, 10–12].
Low molecular weight heparins (LMWHs) are currently
the standard of treatment for DVT in children for its
morepredictablepharmacokineticsandbetterbioavailability
than unfractionated heparin [13]. It is also associated with
lower risk of heparin-induced thrombocytopenia (HIT),
bleeding, and osteoporosis [14]. Other alternatives include,
coumarins, pentasaccharides, and under speciﬁc circum-
stances, thrombolytics. The standard method of LMWH
administration is via the subcutaneous (SC) route. It enables
home treatment, and in the vast majority of patients, it does
not need frequent monitoring once a therapeutic and safe
level has been achieved. However, there may be a subset of
children, in whom the beneﬁts of SC administration may be
outweighed by the potential risks and diﬃculties related to
repeated SC injections. The aim of this pilot project was to
evaluate the safety and eﬃcacy of continuous infusion (CI)
of LMWH in those children with a DVT who already had a
central venous access device in place for other reasons.
2.Methods
Between January 2003 and June 2009, 32 consecutive chil-
dren with a DVT who were treated with LMWH admin-
istered as a CI were identiﬁed at the Children’s University2 Thrombosis
Hospital, Brno. Deep vein thrombosis was diagnosed with
Doppler ultrasound (Siemens, type Antarez, linear probe
VFX 15-3, 10MHZ), increased D-dimer levels (STA Liatest
D-Di,DiagnosticaSTAGO,France)andbyclinicalsymptoms
and signs that included: tenderness, pain, and swelling at the
site of thrombosis, where applicable.
Based on our previous preliminary study, the starting
dose of LMWH in all our patients was 240IU/kg/24hrs
regardless of age and/or thrombosis site [15]. Nadroparin
and Dalteparin were the two routinely used LMWHs at the
Children’s University Hospital. LMWH was administered
by continuous infusion through an intravenous pump, and
the infusion set was changed every 8 hours, with doses
being administered as 80IU/kg/8h diluted in normal saline.
Rate of the infusion was 1mL/hr. Further dosing was
tailored individually for each patient to reach the required
therapeutic anti-Xa level. Blood samples for anti-Xa level
measurements were taken twelve hours after initiation of
infusion and after any dose adjustments or change in
infusion rates.The doseofLMWH was adjustedtokeepanti-
Xa levels between (0.5–1.0IU/mL). Continuous infusion
was not interrupted for more than 2 hours at any one
time, and only in exceptional situations, such as Doppler
ultrasonography evaluation when the patient had to be
transported to the radiology suite from the inpatient ward.
The eﬃcacy of treatment was assessed by the improve-
ment in clinical symptoms as evaluated during regular ward
rounds, as well as by repeated Doppler ultrasonography
(week 1, week 2 and week 6 after the diagnosis of the throm-
bosis) alongwith quantitativeDdimer testing.Anti-Xa levels
(Coamatic Heparin, Chromogenix, Italy) were monitored
daily at least during the ﬁrst ﬁve days of treatment, and then
at frequent intervals depending on the individual subject.
The aim was to achieve a stable anti-Xa level.
Platelet counts were monitored daily, especially in
patients with low platelets. None of the patients had any
renal disorders. Liver function tests were not monitored
routinely in our patients. Therapy with CI of LMWH was
stopped when recanalization of the vein had been achieved
or the thrombus had organized and unchanged on two
consecutive Dopplerultrasound examinations. Patients were
than continued on therapy with either SC LMWH or
switched to vitamin K antagonists (VKA) treatment for at
least3months,andthenwerefollowed foratleastsixmonths
to monitor for any recurrence. The safety of the treatment
was clinically assessed by nurses who recorded any bleeding
or other possible adverse events related to the CI of LMWH.
Descriptive statistics, such as mean, median, minimum
and maximum values and interquartile range (IQR), were
used for description and comparison of duration of treat-
ment, dose of LMWH. and level of anti-Xa.
The study was approved by the local Ethics Committee.
3.Results
There were 18(56%)males and 14(44%)females. Their ages
at the time of treatment varied from newborns to 18 years,
with median of 14 years (IQR 7–16 years). (Figure 1). Site
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Figure 1: Number of patients according to age.
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Figure 2: Thrombus resolution.
of thrombosis included CVL-related thrombosis (n = 9),
DVT of lower extremity veins (n = 11), DVT of upper
extremity veins (n = 3), lower vena cava thrombosis (n = 3),
sino-venous thrombosis (n = 4), and pulmonary embolism
(n = 2). CI of LMWH was tolerated well by our patients.
There were no adverse events or increased bleeding reported
inanyofthesepatientsduringCIofLMWH.Thistherapyled
to complete, recanalization ofthe aﬀected veinin 11 (34.4%)
patients and partial recanalization in 16 (50%) patients. In
5 (15.6%) patients recanalization was not evident despite
therapeutic levels of anti-Xa (Figure 2).
The median of duration of treatment with CI LMWH
was 13.5 days (IQR 9.5–22.0 days). The median dose
of LMWH administered by continuous infusion to reach
required therapeutic anti-Xa levels was 240IU/kg/24h (IQR
220–250IU/kg/24h). The median anti-Xa level achieved
on this protocol was 0.54IU/mL (IQR 0.43–0.69IU/mL)
(Table 1). During the 6 months of followup, no recurrences
were observed in this cohort of patients.
4.Discussion
The aim of this pilot retrospective clinical observational
study was to evaluate an alternate strategy of administering
anticoagulant therapy in the treatment of thrombosis in
children. The standard treatment for DVT is by SC admin-
istration of LMWH. These recommendations are derived
from the REVIVE study, which has shown that LMWH whenThrombosis 3
Table 1: Treatment with continuous infusion of LMWH.
N Mean Median IQR Min-max
Duration of the treatment
with continuous infusion
of LMWH (in days).
32 16.5 13.5 9.5–22.0 5.0–44.0
Weighted dose of LMWH
during the treatment with
CI LMWH (in IU/kg/d).
58 244.5 240.0 220.0–250.0 200.0–330.0
Summarized level of
anti-Xa during treatment
withCI LMWH(in
IU/mL).
103 0.58 0.54 0.43–0.69 0.13–1.41
∗IQR indicates interquartile range.
administered SC appeared to be safe and eﬀective for use in
children with DVT [13, 14].
Based on our own previously published clinical data
[15], we used a dose that was found to be safe and
eﬃcacious in initiating the CI. This study corroborates our
early ﬁndings about the eﬃcacy and safety of treatment
with CI of LMWH. CI with LMWH resulted in at least
partial to complete resolution of the thrombus in 84.6%
of children. This compares favourably with that of SC
administration as published in the literature [16, 17]. Anti-
XalevelsachievedwithCIweresimilartothoseachievedwith
SC administration. It is to be noted that the level of anti-Xa
assessed during SC treatment reﬂects the maximal peak anti-
Xa activity after bolusSCinjection. On the otherhand, levels
of anti-Xa during CI aim to reﬂect the stable steady state of
anti-Xa activity in patients’ plasma. Thus, information about
anti-Xa gained during CI of LMWH may not be comparable
to that of SC administration. Further studies to delineate
the pharmacokinetics of LMWH during CI administration
will be needed to help understand the signiﬁcance of these
levels and tailor them with that of eﬃcacy. In contrast to
the REVIVE study, we have not observed any adverse events
in our patients. This ﬁnding is similar to the ﬁnding by
Hoﬀmann et al. who showed that intravenous (IV) bolus
administration of LMWH is as safe as SCadministration and
is not associated with any higher risk of adverse events [18].
CI of LMWH may be advantageous especially in children
who cannot be treated at home, are admitted to the hospital,
and already have central venous access for other reasons
(ICU patients, oncology patients, or patients with burns of
a signiﬁcant percentage of their body surface). CI avoids
repeated painful SC injections, and thus, may improve a
child’s quality of life. In children with very low weight,
malnourished or those who lack subcutaneous fat, it may
be diﬃcult to give a precise dose via the SC route due to
the very small amount of medication injected. Furthermore,
in very small children and neonates, repeated SC injections
may be limited by body surface available for administration.
When administered by CI,LMWH has a shorter half-life and
this would be beneﬁcial in patients with considerable risk of
bleeding, for example, patients with chemotherapy induced-
thrombocytopenia.In addition, theseoncologypatientshave
increased burdens and hassles associated with the treatment
of their disease and minimizing invasive interventions could
perhaps increase their quality of life.
5.Conclusion
In our patients, the treatment of VTE with LMWH by
continuous infusion was estimated to be safe and eﬃcient
and may provide an alternate method of administering anti-
coagulationinthepaediatricpopulation.Furtherprospective
studies are needed to support the promising ﬁndings of our
pilot clinical observation.
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